WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Pediatric Dermatology News

Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

Raccontata damorningstar.comhealio.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
healio.comStai leggendo13 g fa

Pediatric Dermatology News

Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

originale
morningstar.com11 g fa

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Leggi questa versione → originale

Timeline cronologica

  1. martedì 23 giugno 2026·morningstar.com

    AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe…

    AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

  2. mercoledì 24 giugno 2026·healio.com

    Pediatric Dermatology News

    Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

  3. venerdì 26 giugno 2026·healio.com

    FDA approves Skyrizi for pediatric use in psoriatic disease

    The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active…

  4. venerdì 26 giugno 2026·morningstar.com

    SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

    SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease